| Indication |
Phase |
Sample Size |
Study
Design/Services |
| Allergic Rhinitis |
NDA |
2000 |
Preparation of a NDA including ISS, ISE and
the statistical methodology summary section as well as CSRs for
13 clinical studies |
| Allergic Rhinitis |
4 |
300 |
Randomized,
double blind, placebo-controlled, multi-center study/ Assisted in the study design |
| Allergic Rhinitis |
1 |
30 |
Multiple-dose,
parallel-group, open-label study |
| Allergic Rhinitis |
2 |
200 |
Double-blind,
multi-center, placebo-controlled, parallel group study |
| Allergic Rhinitis |
2 |
50 |
Double-blind,
multi-center, placebo-controlled, parallel group study |
| Allergic Rhinitis |
2 |
200 |
Double-blind,
multi-center, placebo-controlled, parallel group study |
| Allergic Rhinitis |
3 |
400 |
Double-blind,
multi-center, placebo-controlled, parallel group study |
| Allergic Rhinitis |
3 |
200 |
Double-blind,
multi-center, placebo-controlled, parallel group study |
| Allergic Rhinitis |
2/3 |
500 |
Double-blind,
multi-center, placebo-controlled, parallel group study |
| Allergic Rhinitis |
1 |
20 |
Single-dose, parallel
group, open-label study |
| Allergic Rhinitis |
1 |
30 |
Multiple-dose,
crossover, open-label study |
| Allergic Rhinitis |
1 |
25 |
Single-dose, crossover,
open-label study |
| Allergic Rhinitis |
1 |
10 |
Single-dose, crossover,
open-label study |
